120 related articles for article (PubMed ID: 3049862)
1. Systemic effects resulting from topical ocular administration of SCH 33861, a novel ACE inhibitor ocular hypotensive agent.
Watkins RW; Baum T; Tedesco RP; Pula K; Barnett A
J Ocul Pharmacol; 1988; 4(2):93-100. PubMed ID: 3049862
[TBL] [Abstract][Full Text] [Related]
2. Topical ocular hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in conscious rabbits.
Watkins RW; Baum T; Cedeno K; Smith EM; Yuen PH; Ahn HS; Barnett A
J Ocul Pharmacol; 1987; 3(4):295-307. PubMed ID: 3503919
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-converting enzyme inhibitory activity of SCH 31846, a new non-sulfhydryl inhibitor.
Sybertz EJ; Baum T; Ahn HS; Nelson S; Eynon E; Desiderio DM; Pula K; Becker F; Sabin C; Moran R; Vander Vliet G; Kastner B; Smith E
J Cardiovasc Pharmacol; 1983; 5(4):643-54. PubMed ID: 6193364
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin converting enzyme system in the normal canine eye: pharmacological and physiological aspects.
Abrams KL; Brooks DE; Laratta LJ; Barnhill MA; Frazier D
J Ocul Pharmacol; 1991; 7(1):41-51. PubMed ID: 1648119
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of pressor responses to intracerebroventricular angiotensin I by angiotensin converting enzyme inhibitors and their effects on systemic blood pressure in conscious rats.
Baum T; Becker FT; Sybertz EJ
Life Sci; 1983 Mar; 32(12):1297-303. PubMed ID: 6300578
[TBL] [Abstract][Full Text] [Related]
6. SHORT-TERM EFFECT OF CAPTOPRIL ON INTRAOCULAR PRESSURE.
Avtar L; Neki AP; Chandra P
Indian J Physiol Pharmacol; 1999 Jan; 43(1):94-8. PubMed ID: 27093744
[TBL] [Abstract][Full Text] [Related]
7. Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits.
Tomoda F; Lew RA; Smith AI; Madden AC; Evans RG
Br J Pharmacol; 1996 Sep; 119(2):365-73. PubMed ID: 8886422
[TBL] [Abstract][Full Text] [Related]
8. Effect of captopril on ocular irritative response to topical neutral formaldehyde and YAG-laser capsulotomy in the rabbit.
Krootila K; Oksala O; Von Dickhoff K; Palkama A; Uusitalo H
J Ocul Pharmacol Ther; 1995; 11(3):243-52. PubMed ID: 8590256
[TBL] [Abstract][Full Text] [Related]
9. Correlation between lung and plasma angiotensin converting enzyme and the hypotensive effect of captopril in conscious rabbits.
Chen X; Pitt BR; Moalli R; Gillis CN
J Pharmacol Exp Ther; 1984 Jun; 229(3):649-53. PubMed ID: 6327968
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor.
Sybertz EJ; Watkins RW; Ahn HS; Baum T; La Rocca P; Patrick J; Leitz F
J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S105-8. PubMed ID: 2485040
[TBL] [Abstract][Full Text] [Related]
11. Effect of captopril (an angiotensin-converting enzyme inhibitor) on intraocular pressure in healthy human volunteers.
Al-Sereiti MR; Turner P
J Ocul Pharmacol; 1989; 5(1):1-5. PubMed ID: 2654304
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
13. Hypotensive effects of angiotensin II analogues and angiotensin converting enzyme inhibitors in water-deprived Brattleboro rats.
Tomlinson KC; Gardiner SM; Bennett T
J Cardiovasc Pharmacol; 1990 Apr; 15(4):562-8. PubMed ID: 1691384
[TBL] [Abstract][Full Text] [Related]
14. Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.
Haverdings RF; Haas M; Navis G; Van Loenen-Weemaes AM; Meijer DK; De Zeeuw D; Moolenaar F
Br J Pharmacol; 2002 Aug; 136(8):1107-16. PubMed ID: 12163343
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeys.
Sybertz EJ; Baum T; Ahn HS; Desiderio DM; Pula KK; Tedesco R; Washington P; Sabin C; Smith E; Becker F
Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):216-29. PubMed ID: 3036028
[TBL] [Abstract][Full Text] [Related]
16. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
[TBL] [Abstract][Full Text] [Related]
17. [The ocular hypotonic effect induced by an angiotensin-converting enzyme inhibitor (captopril)].
Chiseliţă D; Vancea PP; Hăulică I
Oftalmologia; 1996; 40(1):18-25. PubMed ID: 8714107
[TBL] [Abstract][Full Text] [Related]
18. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology.
DeForrest JM; Waldron TL; Harvey C; Scalese B; Rubin B; Powell JR; Petrillo EW; Cushman DW
J Cardiovasc Pharmacol; 1989 Nov; 14(5):730-6. PubMed ID: 2481187
[TBL] [Abstract][Full Text] [Related]
19. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
20. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
